{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055087","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.511931+00:00","generated_at":"2026-06-02T10:52:10.494414+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aptevo Q1 net loss $6.8M; breast cancer patient stays on ALG.APV-527 >11 months","bullets":["Net loss $6.8M ($9.95 per share) vs net income $2.8M ($17.38 per share) in Q1 2023.","Cash $10.3M at March 31, 2024; pro forma $14.3M after April equity raise.","Heavily pretreated breast cancer patient in ALG.APV-527 Phase 1 achieved stable disease, remains on therapy >11 months, safely transitioned to higher dose.","APVO436 Phase 1b/2 frontline AML dose optimization trial initiation expected Q2 2024; partnered with Prometrika.","R&D expenses down $0.4M to $3.8M; G&A down $0.4M to $3.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055087","json":"https://secwatch.observer/filing/0000950170-24-055087.json","markdown":"https://secwatch.observer/filing/0000950170-24-055087.md","text":"https://secwatch.observer/filing/0000950170-24-055087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024055087/0000950170-24-055087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024055087/apvo-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:52:10.494414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"463adee2a3001041593a82447422578ea400b689","claim":"Aptevo Therapeutics Inc. reported the quarter ended March 31, 2024 results: net income a net loss of $6.8 million or $9.95 per share, EPS $9.95 per share.","evidence_excerpt":"Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024055087/0000950170-24-055087-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"a net loss of $6.8 million or $9.95 per share"},{"label":"EPS","value":"$9.95 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}